Mindmed receives fda type c meeting response for project lucy phase 2b clinical trial

Mindmed finalizes clinical development approach for lsd targeting generalized anxiety disorder as initial indication new york, may 17, 2021 /prnewswire/ -- mindmed (nasdaq: mnmd) (neo: mmed) (de: mmq), a leading clinical stage psychedelic medicine company, announces receipt of type c meeting responses from fda leading to the finalization of the company's clinical development approach for project lucy by selecting generalized anxiety disorder as an initial indication. mindmed is on target to formally submit its investigational new drug (ind) application for project lucy in q3 2021 and expects to launch its phase 2b clinical trial shortly thereafter in q4 2021.
MNMD Ratings Summary
MNMD Quant Ranking